1. Analyzing left-truncated and right-censored infectious disease cohort data with interval-censored infection onset
- Author
-
Universitat Politècnica de Catalunya. Departament d'Estadística i Investigació Operativa, Universitat Politècnica de Catalunya. GRBIO - Grup de Recerca en Bioestadística i Bioinformàtica, Pak, Daewoo, Liu, Jun, Ning, Jing, Gómez Melis, Guadalupe, Shen, Yu, Universitat Politècnica de Catalunya. Departament d'Estadística i Investigació Operativa, Universitat Politècnica de Catalunya. GRBIO - Grup de Recerca en Bioestadística i Bioinformàtica, Pak, Daewoo, Liu, Jun, Ning, Jing, Gómez Melis, Guadalupe, and Shen, Yu
- Abstract
n an infectious disease cohort study, individuals who have been infected with apathogenare often recruited for follow up. The period between infection and the onset of symptomatic disease, referred to as the incubation period, is of interest because of its importance on disease surveillance and control. However, the incubation period is often difficult to ascertain due to the uncertainty associated with asymptomatic infection onset time. An additional complication is that the observed infected sub-jects are likely to have longer incubation periods due to the prevalent sampling. In this paper, we demonstrate how to estimate the distribution of the incubation period with the uncertain infection onset, subject to left-truncation and right-censoring. We employ a family of sufficiently general parametric models, the generalized odds-rate class of regression models, for the underlying incubation period and its correlation with covariates. In simulation studies, we assess the finite sample performance of the model fitting and hazard function estimation. The proposed method is illustrated on data from the HIV/AIDS study on injection drug users admitted to a detoxification program in Badalona, Spain, Ministerio de Ciencia e Innovación, PID2019‐104830RB‐I00; Departament d'Economia i Coneixement de la Generalitat de Catalunya, 2017 SGR 622 (GRBIO); Ministerio de Economía y Competitividad, MTM2015‐64465‐C2‐1‐R (MINECO/FEDER); National Cancer Institute, CA016672; CA193878, Peer Reviewed, Postprint (author's final draft)
- Published
- 2021